Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Benth JŠ, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2018 Oct 15;323:73-77. doi: 10.1016/j.jneuroim.2018.07.011. Epub 2018 Jul 24.

PMID:
30196837
2.
3.

The organisation of physiotherapy for people with multiple sclerosis across Europe: a multicentre questionnaire survey.

Rasova K, Freeman J, Martinkova P, Pavlikova M, Cattaneo D, Jonsdottir J, Henze T, Baert I, Van Asch P, Santoyo C, Smedal T, Beiske AG, Stachowiak M, Kovalewski M, Nedeljkovic U, Bakalidou D, Guerreiro JM, Nilsagård Y, Dimitrova EN, Habek M, Armutlu K, Donzé C, Ross E, Ilie AM, Martić A, Romberg A, Feys P.

BMC Health Serv Res. 2016 Oct 6;16(1):552.

4.

No association of tobacco use and disease activity in multiple sclerosis.

Kvistad S, Myhr KM, Holmøy T, Benth JŠ, Løken-Amsrud KI, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Torkildsen Ø.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 14;3(4):e260. doi: 10.1212/NXI.0000000000000260. eCollection 2016 Aug.

5.

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.

Wergeland S, Myhr KM, Løken-Amsrud KI, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Kvistad SS, Holmøy T, Riise T, Torkildsen Ø.

Eur J Neurol. 2016 Jun;23(6):1064-70. doi: 10.1111/ene.12986. Epub 2016 Mar 21.

PMID:
26998820
6.

Body mass index influence interferon-beta treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Šaltytė Benth J, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Michelsen AE, Aukrust P, Ueland T, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2015 Nov 15;288:92-7. doi: 10.1016/j.jneuroim.2015.09.008. Epub 2015 Sep 26.

PMID:
26531700
7.

Physical therapy provision in multiple sclerosis across Europe: a regional lottery?

Rasova K, Martinkova P, Pavlikoma M, Cattaneo D, Jonsdottir J, Henze T, Baert I, Van Asch P, Santovo C, Smedal T, Beiske AG, Stachowiak M, Kovalewski M, Nedeljkovic U, Bakalidou D, Alves-Guerreiro J, Nilsagård Y, Dimitrova EN, Habek M, Armutlu K, Donzé C, Ross E, Ilie AM, Martić A.

Eur J Phys Rehabil Med. 2015 Dec;51(6):850-2. Epub 2015 Sep 2. No abstract available.

8.

Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.

Beiske GA, Holmøy T, Beiske AG, Johannessen SI, Johannessen Landmark C.

Mult Scler Int. 2015;2015:317859. doi: 10.1155/2015/317859. Epub 2015 Jun 29.

9.

WT1 and interferon-β-vitamin D association in MS: a longitudinal study.

Holmøy T, Esbensen QY, Torkildsen Ø, Wergeland S, Bjerve KS, Beiske AG, Midgard R, Šaltytė-Benth J, Hovdal H, Myhr KM.

Acta Neurol Scand. 2016 Apr;133(4):309-12. doi: 10.1111/ane.12448. Epub 2015 Jun 2.

PMID:
26037530
10.

Cognitive rehabilitation in multiple sclerosis: a randomized controlled trial.

Hanssen KT, Beiske AG, Landrø NI, Hofoss D, Hessen E.

Acta Neurol Scand. 2016 Jan;133(1):30-40. doi: 10.1111/ane.12420. Epub 2015 May 8.

PMID:
25952561
11.

Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.

Røsjø E, Myhr KM, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Šaltytė Benth J, Torkildsen Ø, Wergeland S, Michelsen AE, Aukrust P, Ueland T, Holmøy T.

J Neuroimmunol. 2015 Mar 15;280:21-8. doi: 10.1016/j.jneuroim.2015.02.001. Epub 2015 Feb 11.

PMID:
25773151
12.

Goal attainment in cognitive rehabilitation in MS patients.

Hanssen KT, Saltytė Benth J, Beiske AG, Landrø NI, Hessen E.

Neuropsychol Rehabil. 2015;25(1):137-54. doi: 10.1080/09602011.2014.971818. Epub 2014 Oct 30.

PMID:
25356835
13.

Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients.

Lundqvist C, Beiske AG, Reiertsen O, Kristiansen IS.

J Neurol. 2014 Dec;261(12):2438-45. doi: 10.1007/s00415-014-7515-4. Epub 2014 Oct 1.

PMID:
25270681
14.

Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.

Kvistad S, Myhr KM, Holmøy T, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Løken-Amsrud KI, Lilleås F, Midgard R, Njølstad G, Pedersen T, Benth JŠ, Wergeland S, Torkildsen O.

Mult Scler. 2014 Dec;20(14):1833-40. doi: 10.1177/1352458514533843. Epub 2014 May 19.

PMID:
24842958
15.

Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis.

Røsjø E, Myhr KM, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Torkildsen Ø, Wergeland S, Michelsen AE, Aukrust P, Ueland T, Holmøy T.

J Neuroimmunol. 2014 Jun 15;271(1-2):60-5. doi: 10.1016/j.jneuroim.2014.03.014. Epub 2014 Mar 24.

PMID:
24713402
16.

Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity.

Holmøy T, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Saltytė Benth J, Torkildsen O, Wergeland S, Myhr KM, Michelsen AE, Aukrust P, Ueland T.

PLoS One. 2013 Sep 19;8(9):e75021. doi: 10.1371/journal.pone.0075021. eCollection 2013.

17.

Predictors of executive complaints and executive deficits in multiple sclerosis.

Hanssen KT, Beiske AG, Landrø NI, Hessen E.

Acta Neurol Scand. 2014 Apr;129(4):234-42. doi: 10.1111/ane.12177. Epub 2013 Aug 23.

PMID:
23980635
18.

Alpha-tocopherol and MRI outcomes in multiple sclerosis--association and prediction.

Løken-Amsrud KI, Myhr KM, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JŠ, Torkildsen Ø, Wergeland S, Holmøy T.

PLoS One. 2013;8(1):e54417. doi: 10.1371/journal.pone.0054417. Epub 2013 Jan 22.

19.

Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis.

Løken-Amsrud KI, Myhr KM, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Torkildsen Ø, Wergeland S, Holmøy T.

Mult Scler. 2013 Apr;19(4):451-7. doi: 10.1177/1352458512457843. Epub 2012 Aug 20.

PMID:
22907941
20.

Sleep problems in Parkinson's disease: a community-based study in Norway.

Svensson E, Beiske AG, Loge JH, Beiske KK, Sivertsen B.

BMC Neurol. 2012 Aug 10;12:71. doi: 10.1186/1471-2377-12-71.

21.

Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients.

Saltytė Benth J, Myhr KM, Løken-Amsrud KI, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Holmøy T.

Neuroepidemiology. 2012;39(2):84-93. doi: 10.1159/000339360. Epub 2012 Jul 17.

22.

Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.

Løken-Amsrud KI, Holmøy T, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Sandvik L, Torkildsen O, Wergeland S, Myhr KM.

Neurology. 2012 Jul 17;79(3):267-73. doi: 10.1212/WNL.0b013e31825fdf01. Epub 2012 Jun 13.

PMID:
22700809
23.

ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.

Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Lilleås F, Pedersen T, Bjørnarå B, Dalene F, Kleveland G, Schepel J, Olsen IC, Myhr KM.

Arch Neurol. 2012 Aug;69(8):1044-51. doi: 10.1001/archneurol.2012.283.

PMID:
22507886
24.

Patient satisfaction in rehabilitation of patients with multiple sclerosis.

Holmøy T, Hanssen KT, Beiske AG.

Tidsskr Nor Laegeforen. 2012 Mar 6;132(5):523-6. doi: 10.4045/tidsskr.11.1043. English, Norwegian.

25.

[Neglect of chronically ill].

Beiske AG.

Tidsskr Nor Laegeforen. 2011 Dec 13;131(24):2462. doi: 10.4045/tidsskr.11.1070. Norwegian. No abstract available.

26.

Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires.

Fernández O, Baumstarck-Barrau K, Simeoni MC, Auquier P; MusiQoL study group.

Mult Scler. 2011 Oct;17(10):1238-49. doi: 10.1177/1352458511407951. Epub 2011 Jun 13.

PMID:
21669936
27.

Validation of the multiple sclerosis international quality of life (MusiQoL) questionnaire in Norwegian patients.

Beiske AG, Baumstarck K, Nilsen RM, Simeoni MC.

Acta Neurol Scand. 2012 Mar;125(3):171-9. doi: 10.1111/j.1600-0404.2011.01518.x. Epub 2011 Apr 7.

PMID:
21470195
28.

Fatigue in Parkinson's disease: prevalence and associated factors.

Beiske AG, Loge JH, Hjermstad MJ, Svensson E.

Mov Disord. 2010 Oct 30;25(14):2456-60. doi: 10.1002/mds.23372.

PMID:
20976741
29.

The influence of warm versus cold climate on the effect of physiotherapy in multiple sclerosis.

Smedal T, Myhr KM, Aarseth JH, Gjelsvik B, Beiske AG, Glad SB, Strand LI.

Acta Neurol Scand. 2011 Jul;124(1):45-52. doi: 10.1111/j.1600-0404.2010.01407.x. Epub 2010 Jul 15.

PMID:
20636448
30.

Fatigue in Parkinson's disease: a short update.

Beiske AG, Svensson E.

Acta Neurol Scand Suppl. 2010;(190):78-81. doi: 10.1111/j.1600-0404.2010.01381.x. Review.

PMID:
20586741
31.

Fatigue in multiple sclerosis: associations with health-related quality of life and physical performance.

Smedal T, Beiske AG, Glad SB, Myhr KM, Aarseth JH, Svensson E, Gjelsvik B, Strand LI.

Eur J Neurol. 2011 Jan;18(1):114-20. doi: 10.1111/j.1468-1331.2010.03090.x.

PMID:
20491899
32.

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.

Lancet Neurol. 2009 Jun;8(6):519-29. doi: 10.1016/S1474-4422(09)70085-7. Epub 2009 May 4.

PMID:
19409854
33.

Pain in Parkinson's disease: Prevalence and characteristics.

Beiske AG, Loge JH, Rønningen A, Svensson E.

Pain. 2009 Jan;141(1-2):173-7. doi: 10.1016/j.pain.2008.12.004. Epub 2008 Dec 18.

PMID:
19100686
34.

[Motor symptoms in Parkinson disease].

Larsen JP, Beiske AG, Bekkelund SI, Dietrichs E, Tysnes OB, Vilming ST, Aasly JO.

Tidsskr Nor Laegeforen. 2008 Sep 25;128(18):2068-71. Review. Norwegian.

35.

Depression and anxiety amongst multiple sclerosis patients.

Beiske AG, Svensson E, Sandanger I, Czujko B, Pedersen ED, Aarseth JH, Myhr KM.

Eur J Neurol. 2008 Mar;15(3):239-45. doi: 10.1111/j.1468-1331.2007.02041.x. Epub 2008 Jan 22.

PMID:
18215155
36.

Validation of the Multiple Sclerosis International Quality of Life questionnaire.

Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N, O'Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S, Ammoury N, Beresniak A, Pelletier J; MusiQol study group.

Mult Scler. 2008 Mar;14(2):219-30. Epub 2007 Oct 17.

PMID:
17942521
37.

Quality of life among young patients with ischaemic stroke compared with patients with multiple sclerosis.

Naess H, Beiske AG, Myhr KM.

Acta Neurol Scand. 2008 Mar;117(3):181-5. Epub 2007 Sep 11.

PMID:
17850406
38.

Health-related quality of life in secondary progressive multiple sclerosis.

Beiske AG, Naess H, Aarseth JH, Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Sandberg-Wollheim M, Sorensen PS, Myhr KM; Nordic SPMS study group.

Mult Scler. 2007 Apr;13(3):386-92.

PMID:
17439908
39.

[Do we really want to concentrate on research?].

Beiske AG.

Tidsskr Nor Laegeforen. 2006 Mar 9;126(6):792. Norwegian. No abstract available.

40.

Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis.

Beiske AG, Myhr KM.

J Neurol. 2006 Mar;253(3):377-8. Epub 2006 Mar 6. No abstract available.

PMID:
16502214
41.

[Continuous treatment with levodopa of Parkinson disease].

Lundqvist C, Nystedt T, Reiertsen O, Grotli R, Beiske AG.

Tidsskr Nor Laegeforen. 2005 Oct 6;125(19):2638-40. Norwegian.

42.

[Retraction of article].

Midgard R, Seland JH, Hovdal H, Celius EG, Eriksen K, Jensen D, Heger H, Mellgren SI, Wexler A, Beiske AG, Myhr KM.

Tidsskr Nor Laegeforen. 2005 Aug 11;125(15):2056. Norwegian. No abstract available.

PMID:
16208878
43.

[Optic neuritis--diagnosis, treatment and follow up].

Midgard R, Seland JH, Hovdal H, Celius EG, Eriksen K, Jensen D, Heger H, Mellgren SI, Wexler A, Beiske AG, Myhr KM.

Tidsskr Nor Laegeforen. 2005 Feb 17;125(4):425-8. Norwegian. Retraction in: Midgard R, Seland JH, Hovdal H, Celius EG, Eriksen K, Jensen D, Heger H, Mellgren SI, Wexler A, Beiske AG, Myhr KM. Tidsskr Nor Laegeforen. 2005 Aug 11;125(15):2056.

44.

Pain and sensory complaints in multiple sclerosis.

Beiske AG, Pedersen ED, Czujko B, Myhr KM.

Eur J Neurol. 2004 Jul;11(7):479-82.

PMID:
15257687
45.

[New diagnostic criteria in multiple sclerosis].

Midgard R, Beiske AG, Celius EG, Jensen D, Hovdal H, Mellgren SI, Myhr KM.

Tidsskr Nor Laegeforen. 2003 May 15;123(10):1345-8. Review. Norwegian. No abstract available.

PMID:
12806674
46.

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.

Neurology. 1998 May;50(5 Suppl 5):S46-53.

PMID:
9591522
47.

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G.

J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):421-8.

48.

[Neurologic manifestations caused by Mycoplasma pneumoniae].

Beiske AG.

Tidsskr Nor Laegeforen. 1981 Nov 10;101(31):1765-6. Norwegian. No abstract available.

PMID:
7339966

Supplemental Content

Loading ...
Support Center